Gujarat Themis Biosyn standalone net profit declines 0.31% in the December 2024 quarter
14 - Feb - 2025 12:00 | 45 days ago
Net profit of Gujarat Themis Biosyn declined 0.31% to Rs 12.97 crore in the quarter ended December 2024 as against Rs 13.01 crore during the previous quarter ended December 2023. Sales rose 1.91% to Rs 39.52 crore in the quarter ended December 2024 as against Rs 38.78 crore during the previous quarter ended December 2023.
Board approved merger of Gujarat Themis Biosyn with Themis Medicare
19 - Nov - 2024 12:00 | 132 days ago
The Board of Directors of Gujarat Themis Biosyn (GTBL) and Themis Medicare (TML) have approved a Scheme of Amalgamation of Gujarat Themis Biosyn with Themis Medicare. The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL, the stock exchanges, SEBI, NCLT and other regulatory approvals as may be required.
This amalgamation will result in consolidation of businesses and integration of the entire product value chain under a single amalgamated entity, leading to significant synergies.
Under the scheme, TML will issue and allot 118 equity shares of the face value of Re. 1 each, credited as fully paid-up, for every 100 equity shares of the face value of Re. 1 each fully paid-up, held by shareholders in GTBL.
Board approved merger of Gujarat Themis Biosyn with Themis Medicare
19 - Nov - 2024 12:00 | 132 days ago
The Board of Directors of Gujarat Themis Biosyn (GTBL) and Themis Medicare (TML) have approved a Scheme of Amalgamation of Gujarat Themis Biosyn with Themis Medicare. The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL, the stock exchanges, SEBI, NCLT and other regulatory approvals as may be required.
This amalgamation will result in consolidation of businesses and integration of the entire product value chain under a single amalgamated entity, leading to significant synergies.
Under the scheme, TML will issue and allot 118 equity shares of the face value of Re. 1 each, credited as fully paid-up, for every 100 equity shares of the face value of Re. 1 each fully paid-up, held by shareholders in GTBL.
Gujarat Themis Biosyn standalone net profit declines 15.71% in the September 2024 quarter
25 - Oct - 2024 12:00 | 157 days ago
Net profit of Gujarat Themis Biosyn declined 15.71% to Rs 10.57 crore in the quarter ended September 2024 as against Rs 12.54 crore during the previous quarter ended September 2023. Sales declined 12.19% to Rs 34.72 crore in the quarter ended September 2024 as against Rs 39.54 crore during the previous quarter ended September 2023.
Gujarat Themis Biosyn standalone net profit declines 0.31% in the December 2024 quarter
14 - Feb - 2025 12:00 | 45 days ago
Net profit of Gujarat Themis Biosyn declined 0.31% to Rs 12.97 crore in the quarter ended December 2024 as against Rs 13.01 crore during the previous quarter ended December 2023. Sales rose 1.91% to Rs 39.52 crore in the quarter ended December 2024 as against Rs 38.78 crore during the previous quarter ended December 2023.
Board approved merger of Gujarat Themis Biosyn with Themis Medicare
19 - Nov - 2024 12:00 | 132 days ago
The Board of Directors of Gujarat Themis Biosyn (GTBL) and Themis Medicare (TML) have approved a Scheme of Amalgamation of Gujarat Themis Biosyn with Themis Medicare. The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL, the stock exchanges, SEBI, NCLT and other regulatory approvals as may be required.
This amalgamation will result in consolidation of businesses and integration of the entire product value chain under a single amalgamated entity, leading to significant synergies.
Under the scheme, TML will issue and allot 118 equity shares of the face value of Re. 1 each, credited as fully paid-up, for every 100 equity shares of the face value of Re. 1 each fully paid-up, held by shareholders in GTBL.
Gujarat Themis Biosyn standalone net profit declines 15.71% in the September 2024 quarter
25 - Oct - 2024 12:00 | 157 days ago
Net profit of Gujarat Themis Biosyn declined 15.71% to Rs 10.57 crore in the quarter ended September 2024 as against Rs 12.54 crore during the previous quarter ended September 2023. Sales declined 12.19% to Rs 34.72 crore in the quarter ended September 2024 as against Rs 39.54 crore during the previous quarter ended September 2023.
Gujarat Themis Biosyn standalone net profit declines 0.31% in the December 2024 quarter
14 - Feb - 2025 12:00 | 45 days ago
Net profit of Gujarat Themis Biosyn declined 0.31% to Rs 12.97 crore in the quarter ended December 2024 as against Rs 13.01 crore during the previous quarter ended December 2023. Sales rose 1.91% to Rs 39.52 crore in the quarter ended December 2024 as against Rs 38.78 crore during the previous quarter ended December 2023.
Board approved merger of Gujarat Themis Biosyn with Themis Medicare
19 - Nov - 2024 12:00 | 132 days ago
The Board of Directors of Gujarat Themis Biosyn (GTBL) and Themis Medicare (TML) have approved a Scheme of Amalgamation of Gujarat Themis Biosyn with Themis Medicare. The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL, the stock exchanges, SEBI, NCLT and other regulatory approvals as may be required.
This amalgamation will result in consolidation of businesses and integration of the entire product value chain under a single amalgamated entity, leading to significant synergies.
Under the scheme, TML will issue and allot 118 equity shares of the face value of Re. 1 each, credited as fully paid-up, for every 100 equity shares of the face value of Re. 1 each fully paid-up, held by shareholders in GTBL.
Board approved merger of Gujarat Themis Biosyn with Themis Medicare
19 - Nov - 2024 12:00 | 132 days ago
The Board of Directors of Gujarat Themis Biosyn (GTBL) and Themis Medicare (TML) have approved a Scheme of Amalgamation of Gujarat Themis Biosyn with Themis Medicare. The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL, the stock exchanges, SEBI, NCLT and other regulatory approvals as may be required.
This amalgamation will result in consolidation of businesses and integration of the entire product value chain under a single amalgamated entity, leading to significant synergies.
Under the scheme, TML will issue and allot 118 equity shares of the face value of Re. 1 each, credited as fully paid-up, for every 100 equity shares of the face value of Re. 1 each fully paid-up, held by shareholders in GTBL.
Gujarat Themis Biosyn standalone net profit declines 15.71% in the September 2024 quarter
25 - Oct - 2024 12:00 | 157 days ago
Net profit of Gujarat Themis Biosyn declined 15.71% to Rs 10.57 crore in the quarter ended September 2024 as against Rs 12.54 crore during the previous quarter ended September 2023. Sales declined 12.19% to Rs 34.72 crore in the quarter ended September 2024 as against Rs 39.54 crore during the previous quarter ended September 2023.
